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The generation of induced pluripotent stem cells
(iPSCs) opens up the possibility for personalized
cell therapy. Here, we show that transplanted autolo-
gous rhesus monkey iPSC-derived neural progeni-
tors survive for up to 6 months and differentiate
into neurons, astrocytes, and myelinating oligoden-
drocytes in the brains of MPTP-induced hemiparkin-
sonian rhesus monkeys with a minimal presence of
inflammatory cells and reactive glia. This finding
represents a significant step toward personalized
regenerative therapies.
INTRODUCTION
Autologous transplantation via induced pluripotent stem cells
(iPSCs) is a potential strategy for having readily available match-
ing donor cells and therefore minimizing host immune response
(Okita and Yamanaka, 2011). A recent study showed rejection of
iPSC-derived teratomas by syngenic host mice (Zhao et al.,
2011), casting doubt on the utility of reprogrammed cells for
autologous transplant therapy. To explore the utility and feasi-
bility of the iPSC strategy as an autologous cell therapy in
a preclinical setting, we derived iPSCs from the skin tissue of
three rhesus monkeys (aged 8–10 years) using retrovirus con-
taining the same reprogramming human genes (oct4, sox2,
klf4, andmyc) employed by Yamanaka and colleagues (Takaha-
shi et al., 2007). These iPSCs exhibited characteristic primate
embryonic stem cell (ESC) morphology and expressed pluripo-
tent proteins, including SOX2 and NANAOG (Figures S1A–
S1D), similar to rhesus ESCs (Thomson et al., 1995) and iPSCs
(Liu et al., 2008; Deleidi et al., 2011). They generated teratomas
after being injected into severe combined immunodeficiency
(SCID) mice (Figure S1J).
RESULTS
The rhesus iPSCs were differentiated into neuroepithelia and
then neurons and glia according to our established protocol for646 Cell Reports 3, 646–650, March 28, 2013 ª2013 The Authorsprimate PSCs (Pankratz et al., 2007). We biased the cells
toward a dopaminergic fate using a protocol modified from
the traditional method (Perrier et al., 2004; Yan et al., 2005;
Cooper et al., 2010) with an attempt to examine the dopami-
nergic differentiation potential (Figure 1A). Similar to human
PSCs (hPSCs), rhesus iPSCs differentiated to neuroepithelia
that organized into neural tube-like rosettes and expressed
neuroectoderm transcription factors Pax6 and Sox1 under
a chemically defined medium without the presence of exoge-
nous growth factors in 10–14 days (Figure 1C). The neural
rosettes were expanded in the presence of sonic hedgehog
(SHH, C-24/25, R&D Systems, 200–500 ng/ml) and fibroblast
growth factor 8 (FGF8, 100 ng/ml) for the following 2 weeks
before being differentiated into neurons on a laminin substrate
(Yan et al., 2005). By day 42, the time for cell transplantation,
37% of the cells were bIII-tubulin+ neurons, 16% were S-100b+
immature astrocytes, and the remaining were largely nestin+
progenitors (Figures 1B and 1C). No O4+ oligodendrocytes
were observed at this stage, which usually appear at amuch later
stage during primate stem cell differentiation (Hu et al., 2009).
The major neuronal populations were positive for g-butyric
acid (GABA, 49%) and tyrosine hydroxylase (TH, 16%) (Figures
1B and 1C). Among the TH+ neurons, 87% expressed a floor
plate marker FOXA2 and 64% were positive for the A10 marker
Calbindin, whereas most TH+ neurons also expressed the A9
marker Girk2 (Figures S1G–S1I).
To examine the survival and differentiation of iPSC-derived
neural cells in the primate brain, we created a monkey model
of Parkinson’s disease by unilateral intracarotid artery infusion
of the neurotoxin 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine
(MPTP) (Emborg et al., 2008). All the three monkeys developed
a stable hemiparkinsonian condition, characterized by slight
tremors, bradykinesia (slowness of movement), postural and
gait imbalance, as well as impairment in gross and fine motor
skills in the hand contralateral to the MPTP injection side, as
measured by a clinical rating scale (CRS) (Emborg et al., 2009)
and confirmed by 11C-dihydrotetrabenazine (DTBZ) positron
emission tomography (PET) 12–18 months after the neurotoxin
infusion.
In order to identify the autologous transplants in the host
brain, we first established iPSC lines that carry GFP under the
Figure 1. Differentiation of Grafted Neural
Progenitors
(A) Schematic diagram of iPSC differentiation to
neural progenitors and dopaminergic neurons.
(B) Quantification of cell populations at day 42 (the
day for transplantation).
(C) On day 14, neuroepithelia organize into
rosettes and express Pax6. By day 42, most cells
express Tuj1, and some are positive for TH and
GABA.
(D) Six months posttransplantation, Hoechst-
labeled nuclei and corresponding GFP-labeled
graft in the putamen show nondisrupted cy-
toarchitecture of the grafted area as well as the
graft and cellular projections.
(E) Quantification of neurons (MAP2+), astrocytes
(GFAP+), and oligodendrocytes (MBP+) among
GFP+ grafted cells.
(F) Colabeling of GFP with neuronal (Tuj1, MAP2,
NeuN, TH, GABA) and glial (GFAP, MBP) markers
in the graft. HO, Hoechst. The bar represents
50 mm.
Data are presented as mean ± SE. See also
Figure S1.phosphoglycerate kinase (PGK) promoter through lentivirus
infection and cloning (Figure S1E). Since reporter genes under
ubiquitous promoters tend to be downregulated after primate
PSC differentiation to mature neurons even though the trans-
genes are mostly retained in progenitors and glia (Xia et al.,
2007), we labeled the rhesus neural progenitors at day 30 via
infection with lentivirus carrying the synapsin promoter driving
GFP. Cells at the time of transplantation (day 42), including
immature neurons, were largely positive for GFP (Figure S1F).
To avoid potential overgrowth and to test potential immunolog-
ical rejection, we chose cells that were differentiated for
42 days, a stage commonly used for transplantation into rodent
models (Yang et al., 2008; Deleidi et al., 2011; Hargus et al.,
2010), and transplanted into the striatum and substantia nigra
of the same monkeys 12–18 months post-MPTP lesion without
any immune suppression. Cultures at that stage contained
both postmitotic neurons and dividing progenitors (Figure 1B).
Previous studies indicate that hPSC-derived neural trans-
plants into parkinsonian rhesus monkeys were rejected within
3 months even under daily dosing of cyclosporine (EmborgCell Reports 3, 646–65et al., 2012). A recent study also showed
that hPSC-derived neural grafts were
filled with infiltrating cells by 1 month
(Kriks et al., 2011). We therefore exam-
ined the grafts 6 months posttransplanta-
tion using stereological analysis on serial
coronal sections (Emborg et al., 2009).
Examination under a bright field or with
Nissl staining revealed normal striatal
and nigral cytoarchitecture; the grafts
were not readily discernible in any of the
monkeys (Figures 1D and S2). However,
after immunostaining for GFP or viewing
under a fluorescent microscope, discretegrafts were present in the striatum and substantia nigra of all the
grafted monkeys, ranging from 1.36 to 160.50 mm2 (Figures S1
and S2; Table S1). Stereological cell counts showed that there
were 11,556, 26,655 and 34,321 GFP+ cells in the three
monkeys, respectively (Table S1). The total cell numbers may
be underestimated as GFP expression may be downregulated
in some of the grafted cells, especially neurons.
Analysis of the GFP+ cells indicated that about 63% were
MAP2+ neurons, 22% were GFAP+ astrocytes, and approxi-
mately 10% were myelin basic protein (MBP)+ oligodendrocytes
(Figures 1E and 1F). Most of the GFP+ neurons were located in
the graft, and the GFP fibers extended into the surrounding
host tissue for up to 1.5 mm in one direction. Individual neurons
were also present outside of the graft, expressing Tuj1, MAP2,
and NeuN (Figure 1F), suggestive of maturation. The vast
majority of the GFP+ neurons were GABA+ and few were positive
for TH (Figure 1F). This may explain why we did not observe
obvious behavioral recovery and PET changes (data not shown).
GFAP+ astrocytes were present both in and outside of the
graft, exhibiting filamentous morphology (Figures 1F and 2),0, March 28, 2013 ª2013 The Authors 647
Figure 2. Reaction of Glia and Infiltration of Leukocytes in the Grafts
Shown are representatives of grafts in the putamen revealed by GFP. These
sections are colabeled with antibodies against HLA-DR (for microglia and
macrophages), CD3 and CD8 (for lymphocytes), as well as GFAP (for astro-
cytes). Lower row is the spleen tissue sections as positive controls for HLA-
DR, CD3, and CD8. HO, Hoechst. The bar represents 50 mm.
See also Figure S2.indistinguishable from endogenous astrocytes without GFP
marking. MBP+ oligodendrocytes were localized mainly to the
surrounding of the graft, exhibiting bush-like morphology.
Some of the GFP fibers colabeled with MBP (Figure 1F), sugges-
tive of myelination. In this case, the cell bodies were not labeled.
Therefore, the proportion of oligodendrocytes is underesti-
mated. Immunostaining for Ki67, labeling mitotic cells, showed
no positive cells in the grafts (data not shown), indicating differ-
entiation of grafted progenitors. No cells were positive for OCT4,
NANOG, SOX17, or Brachyury in the grafted brain, indicating the
absence of pluripotent stem cells and cells of nonneural line-
ages. These results indicate that almost all the grafted cells
become neurons, astrocytes, and oligodendrocytes, at least
based on the GFP-labeled population. They also indicate that
overgrowth or tumorigenicity, a major concern of PSC-based
cell therapy, is not present in the present setting.
Human ESC-derived neural grafts in monkeys (Kriks et al.,
2011) as well as teratomas in syngenic mice (Zhao et al., 2011)
were infiltrated with lymphocytes and microglia/macrophages
by 1 month when the animals were sacrificed. Immunostaining
for CD3 and CD8 (for lymphocytes) on our monkey brain
sections showed no obvious difference between the graft and
surrounding host tissues (Figures 2 and S2), whereas the
brain tissue transplanted with human ESC-derived neural
cells (Emborg et al., 2012) as well as spleen tissues (used as
positive controls) were immunoreactive for all the markers. The
lack of lymphocyte infiltration suggests the absence of immune
response. Immunostaining for human leukocyte antigen D-
related (HLA-DR, for microglia and macrophages) revealed
microglial cells throughout the brain, and the microglial cells in
and surrounding the graft exhibited a largely ramified mor-
phology (Figures 2 and S2). However, there was a mild increase648 Cell Reports 3, 646–650, March 28, 2013 ª2013 The Authorsin the intensity of HLA-DR staining in the grafts and surround-
ings, possibly due to MPTP toxicity and/or physical damage
during transplantation. Immunostaining for general GFAP
showed a moderate increase in the intensity (Figure 2). The
increased staining, especially in the graft, is partially due to the
accumulation of GFAP+ astrocytes that were differentiated
from grafted progenitors, as shown by GFP labeling (Figures 2
and S2). Besides the response to MPTP toxicity and physical
(transplant) damages, the mild to moderate increase in the
intensity of HLA-DR and GFAP staining may represent glial
response to the graft that has not yet functionally integrated in
the host brain.
DISCUSSION
Cell therapy is one potential future application of stem cells,
especially of iPSCs, given the possibility of autologous trans-
plantation (Brundin et al., 2010; Redmond et al., 2010; Deleidi
et al., 2011). Although teratomas are rejected by syngenic
mice, stem cell therapy will unlikely employ iPSCs themselves.
Instead, differentiated progenies of stem cells will be used, as
exemplified here. Our results indicate that the autologous
iPSC-derived neural cell transplants in the primate brain are
not rejected, as opposed to the immunological rejection of tera-
tomas by syngenic mice (Zhao et al., 2011). There is no infiltra-
tion of blood-borne cells (macrophages and lymphocytes)
and little response of endogenous glia (astrocytes and micro-
glia), suggesting that one reason for lymphocyte infiltration
and rejection in the syngenic iPSC transplantation (Zhao et al.,
2011) is toward tumor formation and/or pluripotent proteins.
The iPSC-derived neural progenitors survive and produce
mature neurons, astrocytes, and oligodendrocytes in the
monkey brain. Importantly, the grafted neural cells appear to
structurally integrate into the host brain as we barely discerned
the grafts unless by genetic marking, and the differentiated
neurons extend long processes and the oligodendrocytes
participate in myelination.
The present finding, though from limited numbers of non-
human primates, provides proof of principle that iPSC deriva-
tives can engraft and survive in the primate brain, raising hopes
for cell therapy employing human stem cells. The graft size,
however, is relatively small. This may be due to the following
reasons. First, we used relatively mature cells (differentiated for
42 days), which contain over 50% of postmitotic cells. This is
a stage that is commonly used for transplantation into rodent
models (Yang et al., 2008; Deleidi et al., 2011; Hargus et al.,
2010) and that has recently been shown to be relatively safe in
transplanting into the monkey brain (Doi et al., 2012). However,
this could reduce the survival rate of postmitotic cells, especially
TH+ neurons, during and after transplantation into the monkey
brain. Second, we used suspension of individual cells instead
of tissue chunks (Freed et al., 2001; Olanow et al., 2003) or
cell suspension with cell aggregates (Mendez et al., 2005)
that are typically used for transplantation in human and
nonhuman primates, thus further compromising the survival.
The choice of dissociated individual cells was designed for
easy standardization for future application. Third, the number
of grafted cells, especially neurons, is likely underestimated
due to inherent problems relating to random insertion of lenti-
virus and downregulation of the reporter gene along neuronal
differentiation. This technical issue may now be overcome by
the newly developed TALEN (transcription activator-like effector
nucleases) technique to insert a reporter into one of the envy
sites (Hockemeyer et al., 2011) so that the transgene may be
maintained after differentiation. This will allow more accurate
quantification of autologously grafted cells. The above potential
reasons behind the small graft size may form the basis for exper-
imental design for future preclinical studies.
Despite small graft size, the grafted neurons do project axons
over a long distance even under the adult brain environment,
oligodendrocytes produce myelin sheaths, and glial response
is minimal. The scarcity of dopamine neurons in the grafts and
lack of functional improvement in the animals are likely due to
the neural differentiation strategy that does not yield sufficient
numbers of midbrain dopamine neurons besides the reasons
described above. Recently, we (Xi et al., 2012), as well as others
(Kriks et al., 2011; Kirkeby et al., 2012), have developed an effi-
cient strategy for differentiating primate ESCs and iPSCs to
authentic midbrain dopamine neurons, which will allow us to
evaluate individualized cell therapy in the primate model at the
functional level for a longer term.
EXPERIMENTAL PROCEDURES
This study was performed in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the NIH (1996) in
an AAALAC-accredited facility (University of Wisconsin-Madison).
iPSC Generation and Neural Differentiation
A cylindrical sample of skin and subcutaneous tissue was obtained from each
of the three adult femalemacaca mulattamonkeys (8–10 years old), and fibro-
blasts were cultured in DMEM with 10% fetal bovine serum (Hu et al., 2010).
iPSCs (six lines for each monkey) were generated by infecting 1 3 105 fibro-
blasts with retroviruses expressing Oct3/4, Sox2, Klf4, and c-Myc (Takahashi
et al., 2007). The pluripotency was tested by teratoma assay (Hu et al., 2010).
For dopamine neuron generation, primitive neuroepithelia at day 10 of iPSC
differentiation were treated with SHH (C-24/25, R&D, 200 ng/ml) and FGF8
(R&D, 100 ng/ml) from days 14–28 (Yan et al., 2005). The neural progenitors
were then cultured on a laminin substrate in low SHH (50 ng/ml) and FGF8
(50 ng/ml) until day 42 for immunocytochemical analysis and transplantation
(Yang et al., 2008).
MPTP Model and Cell Transplantation
The parkinsonismwas induced by intracarotid artery infusion ofMPTP, and the
parkinsonian state was evaluated by CRS and 11C-DTBZ PET (Swanson et al.,
2011). Twelve to 18 months later, the animals received six MRI-guided stereo-
taxic injections of autologous iPSC-derived cell suspensions (50,000 cells/ml)
into the precommisural (10 ml) and commissural (5 ml) caudate nucleus, the pre-
commisural (10 ml), commissural (10 ml) and postcommisural (10 ml) putamen,
and the substantia nigra (5 ml) ipsilateral to the MPTP injection. The animals
were sacrificed 6 months postgrafting (Swanson et al., 2011).
Immunohistochemical Characterization of Cultured Cells
and the Grafts
Immunofluorescent staining and cellular quantification for coverslip cultures
and free-floating monkey brain sections were performed as described (Yang
et al., 2008) along with spleen tissues as positive controls for blood-borne
cells. The stereological analysis of the grafts on serial cross-sections stained
for GFP using the diaminobenzidine method with Nissl counterstaining was
detailed elsewhere (Swanson et al., 2011). The primary antibodies were listed
in Table S2.SUPPLEMENTAL INFORMATION
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